登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy
ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由南通大学附属医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06756321,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
18 岁 至 70 岁;性别:不限
登记记录的入选字段
Disease progression or relapse ≤ 12 months post-ASCT (relapsed patients must have biopsy-proven relapse).
入选标准第 9 条
Best response of SD after at least 4 cycles of first-line treatment (e.g., 4 cycles of RCHOP), with SD duration not exceeding 6 months after the last dose.
入选标准第 6 条
Best efficacy of the last line of treatment as SD after at least 2 cycles, with the duration of SD not exceeding 6 months after the last dose.
入选标准第 8 条
Previously received anti-CD20/30-CAR T-cell therapy, with CD20 expression positive at enrollment.
入选标准第 22 条
Use of systemic cytotoxic drugs within 2 weeks prior to enrollment, including daily or weekly low-dose maintenance chemotherapy (such as cyclophosphamide, ifosfamide, bendamustine, chlorambucil, methotrexate, vincristine, etc.).
排除标准第 19 条
Male and female subjects unwilling to practice birth control from the time of consent through 12 months after the completion of lymphodepleting chemotherapy or CAR T cells infusion (whichever is longer).
排除标准第 35 条
ECOG performance status ≤ 2.
入选标准第 27 条
Laboratory tests during screening must meet the following requirements, and the subject must not have received cell growth factors (long-acting colony-stimulating factors (G-CSF/PEG-CSF) require a 2-week interval) and platelet transfusions within 7 days prior to hematological assessment:
入选标准第 30 条
Hemoglobin ≥ 60 g/L (without red blood cell transfusion in the last 14 days).
入选标准第 32 条
Total serum bilirubin ≤ 1.5× the upper limit of normal (ULN).
入选标准第 35 条
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5×ULN.
入选标准第 36 条
Creatinine <1.5×ULN and estimated creatinine clearance ≥60 mL/min.
入选标准第 37 条
Brain MRI evidence shows central nervous system lymphoma. Active primary central nervous system DLBL, unless CNS involvement has been effectively treated (i.e., participants are asymptomatic) and there has been a local treatment interval of >4 weeks prior to enrollment.
排除标准第 5 条
Positive for hepatitis B (positive for HBsAg, and/or positive for Hepatitis B core antibody and HBV DNA >1000 copies/mL) and hepatitis C (positive for HCV antibodies), syphilis or human immunodeficiency virus (HIV) infection.
排除标准第 10 条
Women of childbearing potential must have a negative serum or urine pregnancy test result (women who have undergone surgical sterilization or have been postmenopausal for at least 2 years are not considered of childbearing potential).
入选标准第 40 条
Pregnant or breastfeeding women of childbearing age. Chemotherapy poses potential risks to the fetus or infant. Women who have undergone surgical sterilization or are postmenopausal for at least 2 years are not considered of childbearing potential.
排除标准第 34 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06756321,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Patients must meet all of the following criteria to be eligible for the study: Voluntarily participate in the clinical study. The individual or the legal guardian fully understands the study, sign the informed consent form (ICF), and is willing and able to follow and complete all trial procedures. Age ≥ 18 years and < 70 years. Subjects with refractory or relapsed disease after current standard treatments (including allogeneic or autologous hematopoietic stem cell transplantation) who are not suitable for other treatment options, such as a second stem cell transplant. The definitions of relapsed/refractory lymphoma include one of the following situations: Disease progression (PD) as assessed after first-line treatment. Best response of SD after at least 4 cycles of first-line treatment (e.g., 4 cycles of RCHOP), with SD duration not exceeding 6 months after the last dose. PD as the best response to the most recent treatment regimen. Best efficacy of the last line of treatment as SD after at least 2 cycles, with the duration of SD not exceeding 6 months after the last dose. Disease progression or relapse ≤ 12 months post-ASCT (relapsed patients must have biopsy-proven relapse). If salvage treatment is performed after ASCT, the subjects must have no response to or relapsed after the last line of treatment. Relapsed or refractory disease after two or more lines of systemic therapy. Indications included for enrollment in the cohort of anti-CD19-CAR T-cells: CD19+ ALL patients, with bone marrow smear reports showing tumor cells ≥ 5%. CD19+ NHL patients meeting one of the following subtypes: Diffuse large B-cell Lymphoma, not otherwise specified (DLBCL-NOS) Primary mediastinal B-cell lymphoma (PMBCL) Transformed follicular lymphoma (TFL), previously treated for follicular lymphoma and then transformed to refractory DLBCL Mantle cell lymphoma High-grade B-cell lymphoma Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Subtypes of lymphoma included for enrollment in the cohort of anti-CD20/30-CAR T-cells: Previously received anti-CD20/30-CAR T-cell therapy, with CD20 expression positive at enrollment. Lymphoma with dual positive expression of CD20/CD30. Indications included for enrollment in the cohort of anti-CD30-CAR T-cell: CD30 positive HL CD30 positive T-cell lymphoma ECOG performance status ≤ 2. Expected survival of at least 12 weeks. Adequate venous access (for apheresis) and no other contraindications for blood cell separation. Laboratory tests during screening must meet the following requirements, and the subject must not have received cell growth factors (long-acting colony-stimulating factors (G-CSF/PEG-CSF) require a 2-week interval) and platelet transfusions within 7 days prior to hematological assessment: Absolute neutrophil count ≥ 1.0×10\^9/L (the condition of ALL patients is determined by the investigator). Hemoglobin ≥ 60 g/L (without red blood cell transfusion in the last 14 days). Platelets ≥ 50×10\^9/L (the condition of ALL patients is determined by the investigator). Absolute lymphocyte count (ALC) ≥ 0.5×10\^9/L. Total serum bilirubin ≤ 1.5× the upper limit of normal (ULN). Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5×ULN. Creatinine <1.5×ULN and estimated creatinine clearance ≥60 mL/min. Ejection fraction ≥ 45%, with echocardiogram (ECHO) confirming no pericardial effusion (excluding small or physiological amounts), and electrocardiogram results with no clinical significance. Baseline oxygen saturation > 92% without supplemental oxygen. Women of childbearing potential must have a negative serum or urine pregnancy test result (women who have undergone surgical sterilization or have been postmenopausal for at least 2 years are not considered of childbearing potential).排除标准:Exclusion Criteria:
Subjects are not eligible to participate in this study if they meet any of the following criteria: ALL patients with central nervous system (CNS) abnormalities, including CNS-2 and CNS-3 that are of clinically significant neurological changes: CNS-3 disease is defined as detectable tumor cells in the cerebrospinal fluid (CSF) sample with ≥ 5 WBCs/mm\^3, with or without neurological changes. CNS-2 disease is defined as detectable tumor cells in the CSF sample with < 5 WBCs/mm\^3 and with neurological changes. Brain MRI evidence shows central nervous system lymphoma. Active primary central nervous system DLBL, unless CNS involvement has been effectively treated (i.e., participants are asymptomatic) and there has been a local treatment interval of >4 weeks prior to enrollment. Presence of active central nervous system diseases, such as epilepsy, cerebrovascular ischemia/hemorrhage, dementia, cerebellar diseases, or any autoimmune diseases with CNS involvement. A history of or concurrent presence of other malignancies. Clinically significant cardiac disease or arrhythmias that cannot be controlled with medication. Presence or suspicion of fungal, bacterial, viral, or other infections that are uncontrolled or require intravenous antibiotics for treatment. Uncomplicated urinary tract infections and uncomplicated bacterial pharyngitis are allowed. Positive for hepatitis B (positive for HBsAg, and/or positive for Hepatitis B core antibody and HBV DNA >1000 copies/mL) and hepatitis C (positive for HCV antibodies), syphilis or human immunodeficiency virus (HIV) infection. Presence of any indwelling or drainage catheters (such as percutaneous nephrostomy tubes, indwelling Foley catheters, bile drainage tubes, or pleural/peritoneal/pericardial catheters). The use of specialized central venous access devices, such as Port-A-Cath® or Hickman® catheters, is allowed. Prior medication: Use of clofarabine or cladribine within 3 months prior to enrollment, or use of PEG-asparaginase within 3 weeks prior to enrollment. Injection of live vaccines within 4 weeks prior to enrollment. Donor lymphocyte infusion (DLI) within 28 days prior to enrollment. Any medications used for the treatment of GVHD (such as calcineurin inhibitors, methotrexate, mycophenolate, rapamycin, thalidomide) within 4 weeks prior to enrollment, or immunosuppressive antibodies (such as anti-CD20, anti-tumor necrosis factor, anti-interleukin-6, or anti-interleukin-6 receptor) used within 4 weeks prior to enrollment. Immune stimulation or immunosuppressive therapy (such as interferon-α, interferon-β, IL-2, etanercept, infliximab, tacrolimus, cyclosporine, or mycophenolic acid) within 4 weeks prior to enrollment. Any systemic immunosuppressive/stimulatory checkpoint molecule therapy within 4 weeks prior to enrollment (such as ipilimumab, nivolumab, pembrolizumab, atezolizumab, OX40 agonists, 4-1BB agonists, etc.). Use of systemic cytotoxic drugs within 2 weeks prior to enrollment, including daily or weekly low-dose maintenance chemotherapy (such as cyclophosphamide, ifosfamide, bendamustine, chlorambucil, methotrexate, vincristine, etc.). Long-acting growth factors (e.g., pegylated filgrastim) within 14 days prior to leukapheresis, or short-acting growth factors or mobilizing agents (e.g., granulocyte colony-stimulating factor/filgrastim, plerixafor) within 5 days prior to leukapheresis. Radiation therapy within 2 weeks prior to enrollment. Use of pharmacological doses of corticosteroids (>5 mg/day of prednisone or equivalent doses of other corticosteroids) and other immunosuppressive medications must be avoided within 7 days prior to enrollment. Use of venetoclax (BCL-2 inhibitor) within 4 days prior to leukapheresis. Short-acting targeted therapy (e.g., tyrosine kinase inhibitors) within 72 hours prior to leukapheresis. Idelalisib (oral PI3Kδ inhibitor) within 2 days prior to leukapheresis. Lenalidomide within 1 day prior to leukapheresis. Active graft-versus-host disease (GVHD) ≥ grade 2 on the CIBMTR acute GVHD grading system or requires systemic steroids at doses greater than physiological levels. A history of autoimmune diseases (such as Crohn's disease, rheumatoid arthritis, or systemic lupus) resulting in end-organ injury or requiring systemic immunosuppression/systemic disease-modifying agents within the last 2 years. A history of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac diseases within 12 months prior to enrollment. A history of a concomitant genetic syndrome associated with bone marrow failure such as Fanconi anemia, Kostmann syndrome, and Shwachman-Diamond syndrome. A history of symptomatic deep vein thrombosis or pulmonary embolism requiring systemic anticoagulation within 6 months prior to enrollment. Subjects need to be on preventive anticoagulant medication. A history of other malignancies (except for non-melanoma skin cancer, in situ breast/cervical cancer, and other malignant tumors that have been effectively controlled without treatment in the past five years). Use of other investigational products within 30 days prior to screening. Pregnant or breastfeeding women of childbearing age. Chemotherapy poses potential risks to the fetus or infant. Women who have undergone surgical sterilization or are postmenopausal for at least 2 years are not considered of childbearing potential. Male and female subjects unwilling to practice birth control from the time of consent through 12 months after the completion of lymphodepleting chemotherapy or CAR T cells infusion (whichever is longer). Any medical activities that may interfere with the safety or efficacy assessment of the study treatment. In the investigator's judgment, the subject is unlikely to complete all protocol-required procedures and follow-up visits, or to comply with the requirements for participating in the study.
引自 ClinicalTrials.gov, NCT06756321, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06756321,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。